The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Wednesday 15 April 2015, at 4.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden. Participation, etc Shareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday 9 April 2015, and notify Orexo of their intention to attend the meeting not later than on Thursday 9 April 2015 by post to Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by telephone +46 (0) 18 780 88 00, by telefax +46 (0) 18 780 88 88, or by e-mail to beata.augenblick@orexo.com. The notification shall set forth the name, personal/corporate identity number, the number of shares held, telephone number (daytime) and, where applicable, number of assistants (not more than two) that the shareholder intends to bring to the meeting. Shareholders to be represented by proxy should submit a power of attorney (original document) and a certificate of registration or equivalent together with the notification of attendance. A proxy form is available at www.orexo.com. Shareholders whose shares are registered in the name of a nominee/custodian must temporarily re-register their shares in their own names to be entitled to participate in the meeting. Shareholders must inform their nominee/custodian of such re-registration well before Thursday 9 April 2015 by which date such re -registration must have been executed. There are 34,345,697 shares and votes outstanding in Orexo. Proposed agenda 1. Opening of the meeting. 2. Election of chairman of the meeting. 3. Preparation and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two persons who shall approve the minutes of the meeting. 6. Determination of whether the meeting has been duly convened. 7. Speech by the chief executive officer. 8. Presentation of the annual report and the auditor’s report as well as the consolidated financial statements and the auditor’s report on the consolidated financial statements. 9. Presentation of the work performed by the board of directors and its committees. 10. Resolution regarding adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet. 11. Resolution regarding allocation of the company’s result pursuant to the adopted balance sheet. 12. Resolution regarding discharge from liability of the board members and the chief executive officer. 13. Determination of the number of board members, and auditors. 14. Determination of fees for the board members and the auditor. 15. Election of board members, chairman of the board and auditor. 16. Resolution on guidelines for remuneration to the management. 17. Resolution regarding nomination committee. 18. Resolution regarding authorization for the board of directors to resolve to issue new shares. 19. Resolution regarding authorization for the board of directors to resolve to repurchase and transfer of own shares. 20. Resolution regarding adoption of new long term incentive programme. 21. Closing of the meeting. Proposals regarding chairman of the meeting, the board of directors and auditors (items 2, 13, 14 and 15) The nomination committee of Orexo, which consists of Martin Nicklasson (chairman of the board), Eivind Kolding (Novo A/S and chairman of the nomination committee), Björn Odlander (HealthCap) and Claus Berner Møller (Arbejdsmarkedets Tillaegspension), proposes: - that the chairman of the board, Martin Nicklasson, is elected chairman of the meeting (item 2), - that the board of directors shall consist of six board members with no deputy members (item 13), - that the number of auditors shall be one with no deputy auditors (item 13), - that the fees to the board of directors shall amount to SEK 1,900,000 to be allocated as follows: SEK 600,000 to the chairman and, SEK 200,000 to each of the other board members, and in total SEK 300,000 to be allocated to the members of the audit committee so that the chairman of the committee receives SEK 200,000 and SEK 100,000 are allocated between the other members of the committee, that fees to the auditor shall be paid against approved accounts, and that fees to the board members may, if agreed with Orexo, be invoiced by a company, in which case the invoiced fee shall be determined so that it is cost neutral for Orexo (item 14), - that the board members Raymond Hill, Staffan Lindstrand, Martin Nicklasson, Kristina Schauman and Michael Shalmi are re-elected and that David Colpman is elected as new board member, all for the period up until the end of the next annual general meeting (item 15), - that Martin Nicklasson is re-elected as chairman of the board (item 15), and - that PricewaterhouseCoopers AB is re-elected as auditor for the period up until the end of the next annual general meeting (item 15). Allocation of the company’s result (item 11) The board of directors proposes that there shall be no dividend for 2014 and that the results of the company shall be carried forward. Proposal regarding resolution on guidelines for remuneration to the management (item 16) The board of directors proposes that the annual general meeting resolve to approve the board of directors’ proposal concerning principles and guidelines for the remuneration of the company's management in accordance with what is stated below, to apply until the annual general meeting 2016. The board’s proposal principally conforms to guidelines previously applied to the remuneration of the company’s management. “Management” refers to the chief executive officer and the other members of the management group, which in addition to the chief executive officer comprises six persons. The board has appointed a Remuneration Committee to draw up proposals regarding remuneration and other terms of employment for the management. Orexo shall offer terms of employment that are in line with market rates so that the company can recruit and retain skilled personnel. Remuneration to the management shall comprise a fixed salary, variable remuneration, long-term incentive programs, pensions and other customary benefits. Remuneration is based on the individual’s commitment and performance in relation to previously established goals, individual goals and goals for the entire company. Individual performance is continuously evaluated. Fixed salary is generally reviewed on an annual basis and shall be based on the qualitative performance of the individual. The fixed salary of the chief executive officer and the management shall be in line with market conditions. Variable remuneration shall take into account the individual’s level of responsibility and degree of influence. The size of variable remuneration is based on the percentage of set goals met by the individual. Variable remuneration shall amount to no more than 40 percent of the fixed salary of the chief executive officer and not more than 30 percent of the fixed salary for the other members of the management group. Furthermore, the board of directors shall have the option of allocating further variable non-recurring remuneration to the management when the board deems it to be appropriate. Orexo has adopted share-based incentive programs intended to promote the company’s long-term interests by motivating and rewarding the management of the company, among others. The chief executive officer and the other members of the management group are covered by defined-contribution pension plans. The pension premiums paid by the company amount to not more than 20 percent of the chief executive officer’s monthly salary, while premiums for the other members of the management group amount to between 20 and 25 percent of fixed annual salary. The employment agreement with the chief executive officer may be terminated with six months’ notice. Employment agreements with the other members of the management group may be terminated with notice of between three and 12 months. The chief executive officer is entitled to severance pay equivalent to six months’ salary if employment is terminated by the company. The other members of the management group are entitled to severance pay equivalent to between zero and 12 months’ salary if employment is terminated by the company. The board is entitled to, so deemed appropriate on an individual case, assign company work to a board member over and above the board assignment, in which case the board member may be granted reasonable remuneration. Resolution regarding nomination committee (item 17) The nomination committee proposes that the meeting resolves that the company shall have a nomination committee consisting of a representative of each of the four largest shareholders, based on the number of votes held, together with the chairman of the board. If any of the four largest shareholders declines to appoint a member to the nomination committee, additional shareholders are, by order of size, to be offered appointment until four members are appointed. The names of the members of the nomination committee and the names of the shareholders they represent shall be made public not later than six months before the annual general meeting and be based on shareholding statistics provided by Euroclear Sweden AB per the last banking day in August 2015. Unless the members of the nomination committee agree otherwise, the member representing the largest shareholder, based on the number of votes held, shall be appointed chairman of the nomination committee. If a shareholder representative no longer represents the owner or leaves the nomination committee before its work is completed, the shareholder shall be entitled to appoint a new member of the nomination committee. A shareholder who has appointed a member of the nomination committee has the right to remove such member and appoint a new member of the nomination committee. In the event a shareholder that has appointed a member is no longer one of the four largest shareholders, based on the number of votes held, the appointed member shall resign and be replaced by a new member in accordance with the above procedure. Unless special circumstances apply, no changes should be made in the composition of the nomination committee as a result of minor changes in voting rights or changes in voting rights which occur later than two months before the annual general meeting. Changes in the composition of the nomination committee shall be made public as soon as possible. The nomination committee shall prepare and submit proposals to the general meeting on: chairman of the meeting, board members, chairman of the board, board fees to each of the board members and the chairman as well as remuneration for committee work, if any, fees to the company’s auditor, and, when applicable, proposal regarding election of new auditor. Further, the nomination committee shall prepare and propose principles for the composition of the nomination committee to the annual general meeting 2016. The nomination committee shall be entitled to charge the company with costs for consultants and other expenses necessary for the nomination committee to carry out its duties. Resolution regarding authorization for the board of directors to resolve to issue new shares (item 18) The board of directors proposes that the meeting authorizes the board of directors to resolve to issue of new shares on one or several occasions until the next annual general meeting, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. However, such issue of shares must never result in the company’s issued share capital or the number of shares in the company at any time, being increased by more than a total of 10 per cent. The purpose of the authorization is to enable the board to make corporate acquisitions, product acquisitions or to enter into collaboration agreements, or to raise working capital or broaden the shareholder base. Resolution regarding authorization for the board of directors to resolve to repurchase and transfer of own shares (item 19) The board of directors proposes that the meeting authorizes the board of directors to resolve to repurchase, on one or several occasions until the next annual general meeting, as many own shares as may be purchased without the company’s holding at any time exceeding 10 per cent of the total number of shares in the company. The shares shall be purchased on Nasdaq Stockholm and only at a price per share within the price range applicable, i.e. the range between the highest purchase price and the lowest selling price. The board of directors also proposes that the meeting authorizes the board of directors to resolve, on one or several occasions until the next annual general meeting, to transfer (sell) own shares. Transfers may be carried out on Nasdaq Stockholm at a price within the price range applicable, i.e. the range between the highest purchase price and the lowest selling price. Transfers may also be made in other ways, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. Upon such transfers, the price shall be established so that it is not below market terms. However, a discount to the stock market price may apply, in line with market practice. Transfers of own shares may be made of up to such number of shares as is held by the Company at the time of the board of director's resolution regarding the transfer. The purpose of the authorization to repurchase own shares is to promote efficient capital usage in the company and to provide flexibility as regards the company’s possibilities to distribute capital to its shareholders. The purpose of the authorization to transfer own shares is to enable the board to make corporate acquisitions, product acquisitions or enter into collaboration agreements, or to raise working capital or broaden the shareholder base or for use in the context of the company’s incentive plans. Resolution regarding adoption of new long term incentive programme (item 20) The board of directors proposes that the annual general meeting resolves to implement a new performance based long term incentive program for senior executives and key employees within the Orexo group (LTIP 2015) in accordance with items 20 (a) – 20 (e) below. The resolutions under items 20 (a) – 20 (e) below are proposed to be conditional upon each other and for that reason it is proposed that all resolutions are to be passed as one resolution. LTIP 2015 is proposed to include up to approximately 30-40 senior executives and key employees within the Orexo group. LTIP 2015 is a three-year performance-based program under which the participants will be granted, free of charge, performance-based share awards (“Share Awards”) that provide entitlement to a maximum of 135,000 shares in Orexo, in accordance with the terms stipulated below. Proposal to adopt a performance based long-term incentive program (item 20 (a)) The rationale for the proposal LTIP 2015 will replace the “long-term incentive program” currently in place for certain senior executives and key employees within the Orexo Group based on performance-based stock options (“LTIP 2011/2021”). LTIP 2011/2021 comprises in total 2,540,000 stock options, corresponding to a maximum dilution effect of 6 percent, and currently has 40 participants. Whilst the board of directors of Orexo believes that an equity incentive program is an important part of a competitive remuneration package to be able to attract, retain and motivate qualified employees to the Orexo group, the board of directors has continuously evaluated LTIP 2011/2021 to ensure that it fulfils its purposes. Following the implementation of LTIP 2011/2021, the Orexo business has taken a new path in its development by launching Zubsolv and establishing a sizable commercial footprint in the USA with a number of new qualified personnel recruited. Also, the market’s appreciation of this new path has been reflected in the rapid share price development. With reference thereto, the board of directors has decided to launch a new equity incentive program structure, LTIP 2015, based on performance share awards, which is tailored to the current needs of the Orexo group and also in line with market practice for companies in the same phase and industry. The dilution effect of LTIP 2015 will correspond to 0.4 percent after full dilution and the board of directors intends to make annual grants of the now proposed performance shares award structure and such future annual grants will be subject to the approval by the general meeting. As a result of the implementation of a new equity incentive program, no more grants will be made under LTIP 2011/2021 and, thus, the remaining approximately 450,000 stock options in LTIP 2011/2021 still available for grant during 2015 will not be used and therefore cancelled. This will reduce the maximum dilution from the LTIP 2011/2021 from 6 percent to 4.9 percent, and no personnel costs related to the remaining stock options will be accounted for under LTIP 2011/2021. The purpose of LTIP 2015 is to attract, retain and motivate employees of the Orexo group, provide competitive remuneration packages and to align the interests of the senior executives and key employees with the interests of the shareholders. The board of directors is of the opinion that this strengthens the interest for Orexo’s business and also stimulates company loyalty in the future. In light of the above, the board of directors believes that implementation of LTIP 2015 will have a positive effect on the development of the Orexo group and consequently that LTIP 2015 is beneficial to both the shareholders and the company. Conditions for Share Awards The following conditions shall apply for the awards. - The Share Awards shall be granted free of charge to the participants as soon as possible following the annual general meeting 2015 and no later than on 30 June 2015. - Each Share Award entitles the holder to receive one share in the company, free of charge, three years after granting of the Share Award (the vesting period), provided that the holder, with some exceptions, still is employed by the Orexo group. - A prerequisite for entitlement to receive shares on the basis of Share Awards is that the performance conditions for LTIP 2015 have been satisfied pursuant to the terms and conditions specified below. - The number of Share Awards encompassed by LTIP 2015 is to be re-calculated in the event that changes occur in Orexo's equity capital structure, such as a bonus issue, merger or consolidation of shares, new issue, reduction of the share capital or similar measures. - To make the participants’ interest equal with the shareholders’, Orexo will compensate the participants for distributed dividends, if any, during the vesting period by increasing the number of shares that each Share Award is entitled to after the vesting period. - The Share Awards are non-transferable and may not be pledged. - The Share Awards can be granted by the parent company and any other company within the Orexo group. Performance Conditions The Share Awards are to be divided according to two different performance conditions encompassed by LTIP 2015. The performance conditions focus on Orexo’s financial and operational targets for 2015 (“Performance Target 1”) and on the share-price development for the three year vesting period (“Performance Target 2”). Of each participant’s granted Share Awards, 50 percent will pertain to Performance Target 1 and 50 percent will pertain to Performance Target 2. The allotment of shares that each participant later may receive depends on achievement of the established performance targets as described below. Performance Target 1: This target pertains to the fulfilment of the financial and operational targets for the financial year 2015 as established by the board of directors and relates to Orexo’s key KPIs as for example revenue, profitability and achieved milestones, etc. Performance achievement of individual targets is weighted into an overall average performance achievement. The outcome will be measured lineally, meaning that none of the Share Awards will vest unless a minimum threshold of 80 percent of the overall average performance of the financial and operational targets is achieved, and all Share Awards will vest and entitle to one share each if 100 percent of the overall average performance is achieved. When calculating the overall performance achievement, individual targets may account for a maximum of 120 percent achievement, but the overall average performance is capped at 100 percent. If the minimum threshold is achieved 80 percent of Share Awards subject to Performance Target 1 will vest. The board of directors will present the rate of achievement of Performance Target 1 in the Annual Report for 2015. Performance Target 2: This target pertains to the development of the Orexo share price over the period from the date of the annual general meeting 2015 up to and including April 14, 2018. The share price will be measured as the volume weighted average share price 20 trading days prior to measurement date. Measurement dates are date defined as date of the annual general meeting 2015 and April 14, 2018. Should the Orexo share price increase by 60 percent, then 100 percent will be allotted, 66 percent will be allotted should the Orexo share price increase by 40 percent and 33 percent will be allotted should the Orexo share price increase by 20 percent. In between these figures, allotment of shares on the basis of the Share Awards will occur linearly. These categories correspond to a three-year average annual increase of approximately 17 percent, 12 percent and 7 percent per annum. In addition to satisfaction of the Performance Target 2 set out above, for any vesting to occur, the development of the Orexo share price shall have outperformed the Nasdaq Stockholm Pharmaceuticals & Biotechnology PI during the measurement period from the date of the annual general meeting 2015 up to and including April 14, 2018. Allocation The participants are divided into three allocation categories: (i) CEO; (ii) other members of Group Management; (iii) other key personnel. The maximum number of share awards that a participant may be granted in LTIP 2015 depends on the category to which the participant belongs. The limits for each category is defined as the maximum granting value as a percent of annual base salary and will be maximum 75 percent of annual base salary for the CEO, maximum 50 percent of annual base salary for other members of the Group Management and finally maximum 33 percent of the annual base salary for other key personnel. The board of directors shall resolve upon the final allocation of the Share Awards as soon as possible after the annual general meeting. Several factors will be considered to secure recruitment, retention and motivation when deciding upon individual allocations including position within Orexo, individual performance and total value of current remuneration package. Individual allocation cannot exceed the above mentioned limit for the category that the individual belongs to. The share price that is to form the basis for calculating the number of share awards is to correspond to the average last price paid during a given period of trading. This period comprises the first ten days of trading immediately following the date of the 2015 annual general meeting. The share price is then divided by the individual granting value in order to arrive at the total number of Share Awards granted per participant. Preparation and administration The board of directors shall be responsible for preparing the detailed terms and conditions of LTIP 2015, in accordance with the mentioned terms and guidelines. To this end, the board of directors shall be entitled to make adjustments to meet foreign regulations or market conditions. The board of directors may also make other adjustments if significant changes in the Orexo group, or its operating environment, would result in a situation where the decided terms and conditions for LTIP 2015 no longer are appropriate. Prior to finally determining allotment of shares on the basis of Share Awards, the board of directors will assess whether the outcome of LTIP 2015 is reasonable. This assessment will be conducted in relation to the company’s financial earnings and position, conditions in the stock market and other circumstances. Should the board of directors not consider the outcome to be reasonable, the number of shares to be allotted will be reduced. Preparation of the proposal LTIP 2015 has been initiated by the board of directors of Orexo, and has been structured in consultation with external advisers based on an evaluation of prior incentive programs and best market practices. LTIP 2015 has been prepared by the Remuneration Committee and reviewed at meetings of the board of directors. Scope and costs of the program LTIP 2015 will be accounted for in accordance with “IFRS 2 – Share‐based payments”. IFRS 2 stipulates that the Share Awards should be expensed as personnel costs over the vesting period and will be accounted for directly against equity. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. Social security costs will be expensed in the income statement according to UFR 7 during the vesting period. Assuming a share price at the time of implementation of SEK 133, that Performance Target 1 is achieved at 80 percent and that Performance Target 2 is achieved at 50 percent, including a share price increase of 30 percent during the vesting period, the annual cost for LTIP 2015, including social security costs, is estimated to approximately SEK 4.6 million before tax. The corresponding annual cost with full achievement of Performance Target 1 and Performance Target 2, including a share price increase of 60 percent during the vesting period, is estimated to approximately SEK 6.0 million before tax. The costs are expected to have marginal effect on key ratios of the Orexo group. LTIP 2015 will comprise maximum 135,000 shares in total, which corresponds to approximately 0.4 percent of the total outstanding shares and votes in the company. If all outstanding long-term incentive programs in Orexo are included in the calculation, then the corresponding maximum level of dilution amounts to approximately 6.1 percent. Information on Orexo’s existing incentive programs can be found in the Annual Report 2014, Note 28, and on the company’s website, www.orexo.com. Delivery of shares under LTIP 2015 To ensure the delivery of shares under LTIP 2015, the board of directors proposes to introduce a new class of shares, Class C shares. The Class C shares will not be listed, are redeemable and may, upon the decision by the board of directors, be reclassified into ordinary listed shares. The Class C shares will not provide entitlement to dividend payment. The board of directors proposes that the general meeting authorises the board of directors to resolve on a directed issue of Class C shares to Danske Bank in accordance with item 20 (c), and an authorisation for the board of directors to subsequently resolve to repurchase the Class C shares from Danske Bank in accordance with item 20 (d). The Class C shares will then be held by Orexo as treasury shares during the vesting period, whereafter the appropriate number of Class C shares will be reclassified into ordinary shares and subsequently delivered to participants in LTIP 2015. Proposal regarding amendment of the articles of association (item 20 (b)) The board of directors proposes that the annual general meeting resolves to amend the articles of association with respect to the implementation of LTIP 2015 whereby paragraph 4 in the articles of association is supplemented in accordance with the following: “Shares may be issued in two classes, ordinary shares and Class C shares. The ordinary shares share shall carry one vote and the class C shares 1/10 of one vote each. Ordinary shares may be issued up to a maximum number of shares that represents the full share capital of the company. Class C shares may be issued up to a maximum number of shares that represents the full share capital of the company. Class C shares do not entitle to dividends. Upon the company’s liquidation, Class C shares carry equivalent right to the company’s assets as other shares, however not to an amount exceeding up to the quota value of the share. Should the company resolve on an issue of new ordinary and Class C shares, against other payment than contribution in kind, each holder of ordinary and Class C shares has preferential rights to subscribe for new shares of the same class in proportion to the number of old shares held by such holder (primary preferential rights). Shares not subscribed for with primary preferential rights shall be offered for subscription to all shareholders in the company (subsidiary preferential rights). If the number of shares so offered is less than the number subscribed for with subsidiary preferential rights, the shares shall be distributed among the subscribers in proportion to the number of already shares held, or, to the extent that this is not possible, by lot. Should the company resolve on an issue of new shares solely of ordinary shares or Class C shares, against other payment than contribution in kind, all shareholders, irrespective of which class of shares held, are entitled to preferential rights to subscribe for new shares in proportion to the number of shares previously held. The stipulations above regarding preferential rights shall apply mutatis mutandis for new issues of warrants and convertible debt, and shall not infringe on the possibility to resolve on an issue in which the preferential rights of shareholders are waived. If the share capital is increased by a bonus issue, where new shares are issued, new shares shall be issued in relation to the number of shares of the same classes already held. In such cases, old shares of a specific class shall entitle to new shares of the same class. Following a requisite amendment in the articles of association, the aforementioned stipulation shall not infringe on the possibility to issue shares of a new class by a bonus issue. Reduction of the share capital, however not below the minimum share capital, may as resolved by the company’s board of directors or general meeting, be made by redemption of Class C shares. When a resolution on reduction has been passed, an amount corresponding to the reduction amount shall be transferred to the company’s equity reserves, if the required funds are available. The redemption payment per Class C share shall correspond to the quota value of the share. Following notice of the redemption resolution, holders of shares shall promptly receive payment for the share, or, if authorisation from the Swedish Companies Registration Office or a court is required, following notice that the final decision has been registered. Class C shares held by the company, may upon decision by the board of directors be reclassified into ordinary shares. Immediately thereafter, the board of directors shall report the reclassification to the Swedish Companies Registration Office (Sw. Bolagsverket) for registration. The reclassification is effected when it has been registered and the reclassification been noted in the Swedish Central Securities Depository.” Proposal regarding authorisation to resolve to issue Class C shares (item 20 (c)) The board of directors proposes that the annual general meeting resolves to authorise the board, during the period until the next annual general meeting, to increase the company’s share capital by not more than SEK 54,000 by the issue of not more than 135,000 Class C shares, each with a quota value of SEK 0.40. With disapplication of the shareholders' preferential rights, Danske Bank shall be entitled to subscribe for the new Class C shares at a subscription price corresponding to the quota value of the shares. Such issues must not lead to the company’s share capital exceeding the maximum share capital pursuant to the company’s at any given time adopted articles of association. The purpose of the authorisation is to ensure delivery of ordinary shares to participants under LTIP 2015 and to secure for future cash flow effects due to payments of social security costs connected with LTIP 2015. Proposal regarding authorisation to resolve to repurchase Class C shares (item 20 (d)) The board of directors proposes that the annual general meeting authorises the board of directors to decide on the repurchase of up to 135,000 of the company’s own Class C shares in accordance with the following terms and conditions: 1. The board of directors shall have the right to repurchase all issued Class C shares through an offer directed to all holders of Class C shares. 2. The repurchase may be exercised on one or several occasions until the next annual general meeting. 3. The number of repurchased shares may not exceed ten (10) per cent of all issued shares in the company at any given time. 4. The repurchase shall be made in cash at a price of SEK 0.40, corresponding to the share’s quota value. The reason for the proposed possibility to repurchase own shares is that the company shall be able to fulfill its obligations under LTIP 2015. Proposal regarding transfer of ordinary shares (item 20 (e)) The board of directors proposes that the annual general meeting resolves that 135,000 Class C shares, having been purchased by the company by virtue of the authorisation to repurchase its own shares in accordance with item 20 (d) above, following conversion to ordinary shares, may be transferred to participants in accordance with the terms of LTIP 2015. The board of directors’ statements pursuant to Chapter 19, Section 22 of the Swedish Companies Act have been made available together with the proposal. ________________________ A resolution in accordance with the board of directors’ proposal in item 18 and 19 shall only be valid where supported by not less than two-thirds of both the votes cast and the shares represented at the meeting and resolutions in accordance with the board of directors’ proposal in item 20 shall only be valid where supported by not less than nine-tenths of both the votes cast and the shares represented at the meeting. The shareholders are reminded of their right to request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. The annual report and all other documents, including the nomination committees’ motivated statement and the auditor’s report pursuant to Chapter 8 Section 54 of the Companies Act, are available at the company’s office at Virdings allé 32 A, in Uppsala and at www.orexo.se no later than three weeks before the meeting and will be sent to shareholders who so request and who inform the company of their postal address. This notice is a translation of a Swedish notice and in case of any deviations between the both language versions, the Swedish version shall prevail. Uppsala, March 2015 Orexo AB (publ) The board of directors
Notice of Annual General Meeting of Orexo
| Source: Orexo AB
Attachments
